RE: Averaging down.....26 Jan 2022 11:00
OIG in particular has taken a bit of a dip recently - although some of their larger health sector holdings (CIR, EKF, RENX) have seen a bit of price volatility which will impact on NAV. As regards RENX - price performance will be driven by the company achieving its 2022 milestones - FDA approval being the most significant - but getting 20 health system partnerships on board (5 to date), developing current strategic partnerships with private sector, increasing Mount Sinai to 10,000 tests pa, developing the US government veterans contract and the associated GSA - all at the agreed reimbursement of $950 per test. IF these are achieved this year - we could be looking at multiples of the current share price. SB